We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

179 hedge funds and large institutions have $826M invested in Acorda Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more call options, than puts

Call options by funds: $38.5M | Put options by funds: $15.2M

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

16% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 55

3% more funds holding

Funds holding: 174 → 179 (+5)

19% less capital invested

Capital invested by funds: $1.01B → $826M (-$189M)

Holders
179
Holders Change
+5
Holders Change %
+2.87%
% of All Funds
3.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
64
Reduced
55
Closed
19
Calls
$38.5M
Puts
$15.2M
Net Calls
+$23.3M
Net Calls Change
-$2.58M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$16.5M
2
BlackRock
BlackRock
New York
+$15.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
4
Marshall Wace
Marshall Wace
United Kingdom
+$7.23M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.58M

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$29.3M
2
Bank of America
Bank of America
North Carolina
-$7.81M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.62M
4
Deutsche Bank
Deutsche Bank
Germany
-$4.82M
5
First Trust Advisors
First Trust Advisors
Illinois
-$3.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
ASN
126
Advisory Services Network
Georgia
$193K -$113K -52 -34%
MSA
127
Mason Street Advisors
Wisconsin
$191K +$10.9K +5 +5%
QIM
128
Quantitative Investment Management
Virginia
$191K +$224K +103 New
SG Americas Securities
129
SG Americas Securities
New York
$189K +$220K +101 New
MAM
130
Meeder Asset Management
Ohio
$188K +$56.6K +26 +35%
BCM
131
Bayesian Capital Management
New York
$185K +$215K +99 New
BMC
132
Benin Management Corp
Connecticut
$183K – – –
MERSOM
133
Municipal Employees' Retirement System of Michigan
Michigan
$175K +$205K +94 New
AG
134
Aperio Group
California
$173K -$28.3K -13 -12%
Public Employees Retirement Association of Colorado
135
Public Employees Retirement Association of Colorado
Colorado
$171K – – –
GHCM
136
Glen Harbor Capital Management
California
$165K – – –
XK
137
Xact Kapitalforvaltning
Sweden
$164K – – –
TRSOTSOK
138
Teachers Retirement System of the State of Kentucky
Kentucky
$157K – – –
FDCDDQ
139
Federation des caisses Desjardins du Quebec
Quebec, Canada
$138K +$161K +74 New
MCIM
140
Meadow Creek Investment Management
Georgia
$136K – – –
FQ
141
First Quadrant
California
$131K -$115K -53 -43%
SAM
142
Shell Asset Management
Netherlands
$111K -$10.9K -5 -8%
EP
143
Elkfork Partners
Oregon
$107K – – –
SDIC
144
South Dakota Investment Council
South Dakota
$92K – – –
RCM
145
Riverhead Capital Management
Delaware
$87K – – –
TAM
146
Tyers Asset Management
Texas
$78K – – –
NIT
147
NumerixS Investment Technologies
British Columbia, Canada
$77K +$93.6K +43 New
CMBA
148
C.M. Bidwell & Associates
Hawaii
$63K +$74K +34 New
AIP
149
Ameritas Investment Partners
Nebraska
$58K – – –
Zurich Cantonal Bank
150
Zurich Cantonal Bank
Switzerland
$48K – – –
4 5
6
7 8

ACOR Hedge Fund Activity: Q4 2018 in Review

179 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2018, worth a combined $826M — down 19% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 19 closed out — a net gain of 7 holders — while 64 added to existing stakes and 55 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $16.5M. The largest seller was Scopia Capital Management, cutting an estimated $29.3M.

  • 179 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2018, up from 174 in Q3 2018.
  • Funds reported $826M of Acorda Therapeutics stock for Q4 2018, down 19% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q4 2018 and 19 closed out, a net change of +7 holders.
  • The largest Acorda Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $16.5M added.
  • The largest Acorda Therapeutics seller in Q4 2018 was Scopia Capital Management, an estimated $29.3M sold.

Based on aggregated 13F filings for Q4 2018.